Targeted Drug Delivery System: From the Magic Bullet Concept to Advanced Nanomedicine-A Comprehensive Review

Salman Abdul Mobin[1,2], Vaibhav Anant Bhadange[1]*

1 Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post: Somathne, Panvel, Mumbai-410206, Maharashtra, India.

2 Prof. Ravindra Nikam College of B. Pharmacy Morane-Gondur Bypass Road, Gondur, Tal & Dist – Dhule 424002, Maharashtra, India.

***For correspondence** – vbhadange6@gmail.com Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post: Somathne, Panvel, Mumbai-410206, Maharashtra, India.

Abstract: Targeted drug delivery system (TDDS) has emerged as a promising approach to improve therapeutic efficacy by delivering drugs selectively to diseased tissues while minimizing systemic toxicity. Originating from Paul Ehrlich's "magic bullet" concept, targeted drug delivery has evolved remarkably with advances in nanotechnology, biotechnology, and material science, giving rise to sophisticated nanomedicine-based platforms. This review summarizes the fundamental principles of targeted drug delivery, including passive, active, and stimuli-responsive targeting strategies, and discusses the influence of biological barriers and carrier properties on drug distribution and therapeutic performance. Major delivery systems such as liposomes, polymeric nanoparticles, dendrimers, micelles, solid lipid nanoparticles, nanostructured lipid carriers, and biomimetic nanocarriers are critically reviewed with respect to their design, advantages, limitations, and clinical applications. Recent developments in ligand-mediated targeting, antibody–drug conjugates, gene and RNA delivery, and multifunctional nanocarriers are also highlighted. Furthermore, the review addresses key challenges affecting the clinical translation of TDDS, including limited targeting efficiency, formulation stability, large-scale manufacturing, regulatory approval, safety concerns, and cost-effectiveness. Emerging technologies, including artificial intelligence-assisted formulation design, precision medicine, and personalized nanomedicine, are expected to overcome these limitations and accelerate the development of next-generation targeted therapeutics. Overall, this review provides a concise overview of the evolution of targeted drug delivery systems from the "magic bullet" concept to advanced nanomedicine and outlines future opportunities for improving disease management through safer, more effective, and patient-centered drug delivery strategies.

Keywords: Targeted drug delivery systems, Nanomedicine, Magic bullet, Nanoparticles, Passive targeting, Active targeting, Stimuli-responsive drug delivery.

How to cite this article: Salman AM, Bhadange VA. Targeted Drug Delivery System: From the Magic Bullet Concept to Advanced Nanomedicine—A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(70s): 80-95.
DOI: 10.25258/ijddt.16.70s.9

Introduction

Drug delivery technology has progressed significantly during the last 70 years. Modern pharmacy relies heavily on carrier-based medication delivery methods, particularly those using nanometer-sized particles. These carriers have significant benefits over standard drug delivery methods, successfully resolving disease treatment problems.[1,2] The term "target" refers to a specific organ, cell, or collection of cells that requires medical attention for acute or chronic problems. Targeted drug delivery is an intelligent medication delivery system that efficiently provides patients with their medications. Drug delivery encompasses the techniques, formulations, methods, and processes used to move medicinal substances into the body to accomplish therapeutic effects.[3] the ultimate purpose of medication delivery research is to assist patients by creating clinically viable formulations that have improved dramatically over the previous several decades, resulting in the creation of diverse therapeutic formulations that improve patient compliance and convenience.[4] The typical drug delivery method absorbs the medication across a biological membrane, while the targeted release system delivers the drug in a dose form.[5] the development of innovative targeted drug delivery systems has received significant focus in the last several years. These systems provide focused, regulated, and sustained distribution while meeting practical needs and enhancing the therapeutic effectiveness of both new and existing drugs.[6] Targeted drug delivery system advantages of this system over traditional ones include excellent solubility and reduced complexity. The medication has excellent absorption, a longer half-life, and requires less volume for distribution. These medications have higher specificity and therapeutic index compared to traditional drug delivery methods.[7] Targeted drug

delivery selectively delivers medication to the site of action, avoiding non-targeted organs, tissues, or cells. This differs from traditional drug delivery systems. Prevents the medication from having any detrimental effects on healthy tissue by maintaining the body's required levels of plasma and tissue drug. Prevents the medication from having any detrimental effects on healthy tissue by maintaining the body's required levels of plasma and tissue drug.[8] Paul Ehrlich, a microbiologist, presented the idea of medication delivery in the form of a magic bullet, which inspired the design of targeted delivery systems. These medications combine two or more medicines into a single dosage for sequential loading dosage and a maintenance dose, both of which are administered in a sustained-release manner. [9] Targeted drug delivery systems integrate many fields of research, this approach utilizes molecular biology, pharmacology, the science of polymers, and biological conjugation chemistry to deliver a drug to a specific location rather than distributing it throughout the entire body or organ. Therapeutic compounds' pharmacokinetics, pharmacodynamics, particular toxicity, immunogenicity, and biorecognition must all be monitored and adjusted by targeted drug administration.[10] Since the 1960s, liposomes, polymer micelles, dendrimers, drug nanocrystals, drug-polymer conjugates, and drug-protein conjugates have been referred to as "nanoparticles that."[11]



Figure. 1 Targeted drug delivery

The Concept of the Magic Bullet

The idea of precisely delivering medications to the exact location where they would have the desired effect originates with the "magic bullet" theory.[12] A hundred years ago, Paul Ehrlich proposed the idea of using "magic bullets" to target a virus in a way that wouldn't damage the host organism. The concept was very motivating for cancer treatment analysts.[13] Screening for toxic pharmaceuticals was the first phase in Ehrlich's two-step process for his magic bullet concept, followed by making toxic drugs more targeted and less harmful.[14] He clearly imagined a world where finding a treatment would be simple using compounds that were highly selective for the harmful germs and completely inert toward the host. The phrase "magic bullet" comes from the fact that this would have an adverse effect on the parasite within the host plant while having almost little negative impact on the host tissue.[15] The magic bullets of a shooter target the enemies precisely; therefore, Ehrlich expected site-specific solutions to learning how to fire magic bullets. Nanometer-scale devices, or "nanomedicines," as they are now called, were developed as a result of this fascinating idea, which inspired researchers to study the topic for over a century.[16] The Ehrlich magic bullet idea states that medications should only interact with the target molecule and go straight to their anticipated locations in the body. Nevertheless, get to their destinations, pharmaceuticals must navigate intricate pathways and interactions, and they may interact with several targets, leading to adverse consequences tragically, without these route interactions, no medicine or drug delivery method has ever directly reached the physiological goal. The medication is a "magic shotgun" a "magic bullet," since it interferes with several targets. We still have a long way to go before we can achieve the magic bullet goal.[17] additionally, the potential to significantly increase drug concentration in target compartments without negatively affecting non-target compartments, reduced drug amount, which lowers treatment costs, and easier drug-administration techniques are all encouraging benefits of targeted drug delivery. Drug targeting often results in improved efficacy, modified pharmacokinetics, regulated biodistribution, increased localization specificity, reduced toxicity, reduced dose, and improved patient compliance.[12]



Figure. 2 Reasons of drug targeting

Characteristics of targeted drug delivery systems.[18]

- It should be nontoxic, biocompatible, biodegradable, and physiochemical stable In vitro-in vivo
- Restrict medication distribution to obtain target cells, tissues, or organs and should have uniform capillary distribution.
- Controllable and predictable rate of drug release.
- Drug release does not impact the drug activity.

- A dose of medication released that is therapeutic.
- Very little medication seeps out while in transport.
- The carriers used must be easily biodegradable.
- The delivery mechanism should be inexpensive, reproductive, and easy to prepare.

Creation of drug delivery systems

Figure. 3 Creation of drug delivery systems

Targeted medication is required.[19]

Targeted drug delivery system implies a particular organ or a cell or group of cells, which is a chronic or urgent disease that needs treatment. A drug carrier is one of the particular molecules required for successful delivery of loaded medicine to a pre-selected location. The medication carrier should be biodegradable or easily removed from the body without any problem. Targeted drug delivery system is preferred over traditional drug delivery system due to unsatisfactory drug performance in terms of pharmacodynamics, pharmacokinetics, pharmaceuticals, and Pharmacotherapeutics (refer to Figure no. 4) Targeting medications to a specific location using optimal drug delivery system.

Basic principles and applications of targeted drug delivery systems.

Drug targeting's basic principle is to minimize the drug's concentration in the nontargeted area while delivering a high concentration to the targeted spot. This idea helps to maximize the therapeutic benefits of the medication while reducing adverse effects brought on by greater dosages, nontarget concentrations, and multitarget interactions.[20]



Figure. 4 Targeted medication is required.

Additionally, targeting reduces undesirable interactions between the medicine and bioenvironmental aspects that influence drug access to certain bodily regions.[21] Drug targeting encompasses the pharmacological carrier, the location of the target, and the coordinated behavior of the drug. The drug's target is the particular organ, cell, or cluster of cells in an acute or chronic illness that has to be treated. The carrier is a specifically designed molecule or system that is necessary for the loaded medicine to be transported efficiently toward certain locations.[22] A drug-targeting complex should ideally be In vitro and in vivo physicochemical stability, biochemically inert, biodegradable, biocompatible, atoxic, and nonimmunogenic. Additionally, it need to be fast and simple to remove from the body. Have a predictable and regulated pattern of drug release, be fairly easy, repeatable, and economical to prepare, and have little drug leakage while in transit.[23]



Figure. 5 Types of targeted drug-delivery systems

Various approaches are used to help target specific body sites, as depicted in.[24]



Figure. 6 Active and Passive Targeting

Passive targeting is the term for medication administration that focuses on systemic circulation. This technique relies on the body's natural response to the physicochemical properties of the drug or drug-carrier system, resulting in the accumulation of the drug or drugs at the targeted site of interest, such as tumor tissue.[25] nanoparticles guided to enter blood vessels more often at the illness location when utilized as carriers in passive targeting, which offers the chance for substantial drug buildup at the intended location. Slow lymphatic drainage or the enhanced permeability and retention effect facilitates this process. Conversely, a particular ligand-receptor interaction known as "active targeting" occurs during extravasation and blood circulation.[26] The main factor is the biological interaction between target cells and the ligands attached to nanoparticles. Many ligand types, including proteins, polysaccharides, nucleic acids, peptides, and tiny molecules, have been used for this purpose.[27] Tumors are defined by significantly impaired vascular architecture and insufficient lymphatic drainage, as shown by the elevated permeability and retention effect. These tumor features are expected to make tiny nanocarriers perfect for inactive targeting of anticancer medications, as they are smaller than normal blood vessel spaces and can readily reach and quickly detect malignancies. Consequently, recent studies have shown that the interendothelial gaps on tumors do not contribute to the transport and deposition of nanoparticles into solid tumors. According to one, endothelial cells allow up to 97% of nanoparticles to enter tumors during active processes.[28] these studies imply that the enhanced permeability and retention effect in clinical settings involving cancer patients has not yet been validated. Active transport pathways, as opposed to more passive ones like the enhanced permeability and retention effect, are anticipated to be superior for the absorption of targeted nanoparticles from the circulation into the tumor microenvironment.[29] Even while developing targeted nanoparticles has many potential advantages, especially in cancer chemotherapy, the efficacy of current nanodrugs is not noticeably better than that of the original pharmacological treatments. Because of the intricate relationships between tumor pathophysiology and nanodrug size, this results in inadequate and insufficient penetration of nanodrugs into tumor tissue. Some of the proven methods for this include surface modification, dimensional alteration, carrier charge inversion, and remodeling the microenvironment of tumor tissues, encouraging nanodrug penetration into tumors. Cancer treatment still faces several obstacles, and effective tumor targeting is far from complete, despite promising penetration-enhancing techniques. As a result, higher treatment effectiveness, less adverse effects, and more bioresponsive Drug delivery and targeting systems are needed.[30]

First-, Second-, Third-, and Fourth-Order Targeting.[31]

First order targeting: The drug carrier system is distributed to the target location or organ's capillary bed. For example, the brain ventricles, peritoneal cavity, multiple cavities, lymphatics, etc.

Second order targeting: It consists of delivering medications to targeted cells, including tumor cells or Kupffer cells.

Third order targeting: Third-order targeting refers to the intracellular localization of the drug-carrying unit by endocytosis or receptor-based ligand-mediated drug carrier system entrance, in which drug release or gene delivery to the nucleolus is caused by lysosomal breakdown of the drug complex.

Figure. 7 Levels of active drug targeting

Local and Systemic Targeting

Locally targeted systems are useful targeting techniques whose main objective is to deliver the medication to the local location for the treatment of local illnesses. When systemic targeting is used, the release of these restorative systems occurs via an intrusive method, including the introduction of nanotechnological systems intravenously. Following the drug's diffusion inside the body, these systems distribute it throughout the body. The primary constraints of these systems derive from the detrimental effects of the medications on a particular tissue.[8]

Inverse, Dual, Double, and Combination Targeting.

Inverse Targeting: The reticuloendothelial system will become saturated with the blocking of its defensive mechanisms if a blank colloidal carrier prevents the system's natural function to reduce its passive drug absorption. Inverse targeting is the name of this method.[32]

Dual Targeting: The carrier molecules in this targeting strategy have their own therapeutic action, which enhances the drug's therapeutic efficacy. For example, an antiviral medication may be loaded onto a carrier molecule with its own antiviral action, and the drug conjugate's net synergistic impact has been noted.[33]

Double Targeting: Targeting a carrier system using both temporal and spatial approaches may be referred to as double targeting. When it comes to directing medications to certain organs, tissues, cells, or even subcellular compartments, spatial location matters.Temporal delivery, on the other hand, refers to managing the drug's delivery motion to the target location.

Combination Targeting: Combination targeting is a targeted delivery technique that directly approaches a target using polymers, carriers, and molecularly specific homing devices.[34]

Physical, Chemical, and Biological Targeting

Physical targeting: Physical targeting technologies localize molecules to specific regions based on their size, content, or other characteristics that aren't specifically designed to bind to a biological receptor. This kind of targeting uses particular cues, such as glucose concentration, as well as environmental changes, such as pH, temperature, light intensity, electric field, and ionic strength, to localize the drug carrier to a predefined spot. This method has been discovered to be excellent for both tumor targeting and cytosolic delivery of genetic material or entrapped drugs.[35]

Chemical targeting: Chemical targeting is the process of locating agents in specified regions by using site-specific Prodrug. Agents may also be guided to certain areas by means of enzymatic or chemical mechanisms that target a vehicle or regulate the agent's release or activity.[20]

Biological targeting: Biological targeting enables localized agents to target certain regions by using proteins, peptides, antibodies, or other biomolecules with a particular affinity for receptors, sites, or other biological targets. Furthermore, vector systems, including cells, tissue, or other specialized promoters, may be used to direct gene expression to specified locations.[36]

Location-Based and Disease-Based

Delivering drugs to certain cells, organs, and organelles using location-based techniques is known as targeted drug delivery. The gastrointestinal tract, brain, respiratory tract, and intracellular targeting are a few instances of location-based targeting. Drug-loaded nanocarriers, proteins, and antibodies are an instance of pharmacological agents that may be delivered intracellularly to guarantee that the therapeutic effect is delivered to the nucleus or certain organelles.[37] this kind of targeting is modeled by floating medication delivery, where antibiotic, antiviral, and antifungal drugs are absorbed from very precise gastrointestinal tract areas. To target various areas, such as the colon, lymph nodes, small intestine, and stomach/duodenum, several oral controlled-release techniques have been devised. While disease-based targeted delivery is a site-specific therapy that targets infectious diseases and malignancies, polymer-based medicine administration and steam-like dopamine-liposome conjugates show effective brain targeting with minimal degradation throughout circulation. Using a nanodrug delivery system to treat infections may provide a workable substitute for antibiotic treatment.[38] it is a novel idea to design nanovaccines with enhanced cellular responses and advanced targeting. Targeting some significant infections for persistence inside the cell using specific and specialized methods is currently being explored. These include using antimicrobial agents to functionalize nanoparticles.[3]

Vehicle/Carrier Systems for Targeted Drug Delivery.

Drug carriers, sometimes referred to as drug vectors, are the most important component needed for the loaded medication to be successfully transported to the desired target. They distribute, hold, and carry the medication to the target's location. Through minor structural changes, they are able to carry out these particular tasks. Current drug delivery technology has improved by taking into account a number of variables, including time for the best drug delivery, pharmacokinetic processes, and bioavailability.[39] Targeted drug delivery systems need particular carrier systems based on the kind of targeting mechanism. With the use of a spacer moiety, targeted drug delivery

carriers or vehicles are specially designed vectors that can hold the drug within or on them by bonding, encapsulation, or both. Polymeric carriers that use these drug delivery techniques include liposomes, nanoparticles, lipoprotein-based carriers, and micelles.[18] Toxic, stable, nonimmunogenic, biocompatible, and biodegradable drug delivery vehicles are desirable; they should also be simple to eliminate from the body and invisible to the host's defense mechanisms.. Additionally, the drug should be able to reach its destination, pass through tumor vasculatures and barriers when needed, have the best release characteristics at the target site, and (for nanocarriers) have little to no drug leakage before that target site. Additionally, carriers must have straightforward, repeatable, and reasonably priced preparation methods.[40,41] The biodistribution characteristics of the medication and carrier material may be controlled to provide the best possible target selectivity and specificity for the drug delivery systems. Using both parties' physicochemical and biological characteristics, the biodistribution profile is established.[42] Similarly, designing a beneficial nanoparticulate system requires consideration of both medication release and polymer biodegradation. All things considered, the release procedure depends on the matrix components' solubility, diffusion, and biodegradation.[43]

Colloidal Carrier Systems

Colloidal drug delivery systems are targeted vesicles of a specific or vesicular dose form that are nanoscaled. These consist of ceramics, liposomes, niosomes, nanospheres, and other emulsions. These drug carriers have the potential to modify the distribution pattern while dissolving or transferring the active treatment within or near to the target. They also sequester, convey, and retain the drug throughout the process. They are often divided into two categories: vesicular and microparticulate systems.[44]



Figure. 8 Colloidal Carrier Systems

Vesicular Carrier Systems

Novel vesicular drug delivery systems aim to spread the drug in a site- and rate-controlled manner in order to achieve therapeutic objectives. With several methods of administration, these carriers have recently emerged for controlled and targeted drug delivery.[45] To increase the therapeutic index, solubility, stability, and quick degradation of pharmacological molecules, vesicular drug delivery methods are used.[46] The most well-known development in vesicular carrier systems is nanosomes. These are tiny, vesicular carrier structures that transport medications to the intended location. They come in a variety of forms, including ethosomes, liposomes, niosomes, and transferosomes. Each of these vesicular carriers is a generation of nanosomes, and they differ from one another in terms of their composition and vesicular properties during manufacture, storage, and preparation conditions, and intended therapeutic uses. The table provides a summary of these compositional and structural variations.[47]

Table. 1 Differences in nanosomal vesicular carriers

Nanosome	**Main component**	**Uses**	**Special properties**
Liposomes	Phospholipids scattered across an aqueous solution.	used for targeted drug administration via the mouth, skin, and lungs	Unstable, requires particular preparation and storage
Niosomes	Charge-inducing substances, cholesterol, and nonionic surfactants	Both lipophilic and amphiphilic drug carrier	No special preparation or storage is needed; it is stable.
Transferosomes	A buffer solution is made up of color, phosphatidylcholine, surfactants, and a little bit of alcohol.	Use deeper layers of the epidermis to give medication Transdermally.	Ultra flexible and deformable vesicles.
Ethosomes	High amounts of water, cholesterol, phospholipids, alcohol, and dye.	Controlled transdermal delivery.	Soft and novel vesicle.

Liposomes

Liposomes are lipid-bilayer-structured, simple, tiny, nanoscale lipoidal vesicles. The aqueous core of these bilayers is completely encased in a lipid-molecule-based membrane, allowing for the effective entrapment of both hydrophilic and lipophilic drugs. Lipophilic drugs are captured by the bilayer membrane, whereas hydrophilic medications get trapped in the central aqueous core.[48]

Liposomes are made to be used in pulmonary, topical, and targeted oral drug delivery.[49] Liposomes are made up of several layers and internal and exterior components. Typically, liposomes are composed of water, hydrophilic polymer-conjugated lipids, cholesterol, and natural or synthesized phospholipids. Generally speaking, cholesterol is employed to decrease the permeability of water-soluble compounds across the membrane while increasing bilayer stability and membrane fluidity. Liposomes offer a unique benefit since the lipid membrane is formed from physiological lipids, reducing the possibility of toxicity.[50,51] They may be made as semisolid preparations (gel, cream), solid forms (dry powder), or liquid dose forms (suspension). Additionally, they may be used topically or given parenterally.[52] following systemic (often intravenous) administration, liposomes simply collect within the body because of their tiny size and extended circulation, which allow them to extravasate. The similarities between lipid vesicle bilayers and natural membranes, along with lipid vesicles' ability to adjust and mix with the fluid nature of cell membranes, support the use of liposomes in topical applications. Because of their moisturizing and restorative properties, liposomes were first used in the dermatological sector.[48]



Figure. 9 Liposomes

Niosomes

Niosomes are a new type of nanometric drug delivery system. The medicine is contained in vesicles made of two layers of nonionic active surface agents, as the name suggests. Since they are nonionic, they are less harmful and improve the drug's therapeutic index by concentrating their effects on certain cells, which makes them appealing drug delivery systems. The physicochemical characteristics of liposomes and niosomes are comparable, with little difference based on the manufacturing techniques and bilayer composition. Niosomes are mostly made up of surfactants, while liposomes are made up of phospholipids. Since niosomes are greatly more stable than liposomes, they don't need any particular preparation or storage conditions. This may lower the cost of production.[53] simply put, liposomes and niosomes' limited skin permeability, vesicle dissolution, drug leakage, aggregation, and fusion make them unsuitable for transdermal delivery. Newly created carrier systems called transferosomes overcome these obstacles and are able to effectively deliver drugs with both large and low molecular weights via the transdermal route.[54]



Figure.10 Niosomes

Transferosomes

The Latin word "transfere," which means "to carry across," and the Greek word "soma," which means "body," give rise to the term "carrying body." Phosphatidylcholine and an edge activator combine to form a special kind of liposome called a transferosome. The specialized, ultradeformable (ultraflexible) lipid supramolecular aggregates known as transferosomes have the ability to pierce human skin.[55] An aqueous compartment within and an exterior lipid bilayer containing edge-activator surfactants like sodium cholate, Span 80, and Tween 80 make up their structure. They act as penetration enhancers, facilitating drug penetration of the stratum corneum and beyond by disrupting its highly organized intercellular lipids. [56] They act as medicinal delivery systems for proteins and peptides, including insulin, bovine serum albumin, and vaccines. Their

benefits include improved site specificity, reduced doses for skin diseases, and improved overall drug safety. Their excellent penetration and flexibility make them useful for the effective delivery of nonsteroidal anti-inflammatory drugs such as diclofenac and ibuprofen.[57]

Ethosomes

Other vesicular carriers that are used in medication delivery include ethosomes. They are less effective in penetrating biological membranes, especially the skin, but they can do so more easily than liposomes. Composed of phospholipids, water, and alcohol (ethanol and isopropyl alcohol), they are mostly utilized for transdermal administration of medications. Hydrophilic and impermeable drugs may be administered transdermally using ethersomes, which are primarily employed to substitute liposomes in the transdermal drug administration method.[58]

Microparticulate Systems

A microparticulate drug delivery system allows for the prolonged, controlled delivery of drugs. "The particles having a diameter in the 1-1000 μm size range" is a good way to describe microparticles. Albumin microspheres were proposed by Kramer in 1974 as a novel drug delivery system**.** Drugs may be delivered using microparticulate systems in solids, liquids, and gases. The resulting microparticles may be delivered ocularly, intramuscularly, pulmonaryly, intraperitoneally, intra-organically, nasally, etc., or directly to the site of action. A microparticulate drug delivery system may be used to deliver proteins, nucleic acids, and vaccinations. Microparticles shield the drug from its environment.[59] They thus serve a vital role as drug delivery system working to reduce adverse effects and increase the bioavailability of traditional medications. Microparticulate systems includes microparticles, nanoparticles,, and magnetic microspheres.[60]

Polymeric Carriers for Targeted Drug Delivery System

They are widely used in medicine delivery because they have unique properties that no other material has been able to match.. Polymer advancements have produced a number of novel drug delivery systems, and careful investigation of bulk and surface characteristics has helped to improve the effectiveness, safety, and efficiency of medical treatment. In advanced drug delivery systems, polymers are crucial because they may be utilized as excipients and to aid in delivery, enabling targeted and controlled drug release. [61] A biodegradable polymer is used to create micro- and nanospheres, which allow for controlled medication release at specific locations. Polymeric nanocarriers, including poly(D,L-lactide-co-glycolide), have shown encouraging pharmacokinetics at the cellular and whole-body levels.[62] Generally speaking, polymer-based drug nanocarriers have the potential to significantly improve the solubility of hydrophobic medications, reduce their cytotoxicity to healthy tissue, prolong the time that medications remain in the bloodstream, facilitate the entry of nanoparticles, and improve the effectiveness of use. Studies on the usage of synthetic polymers such as polyethers, polyamides, and polypeptides have been more prevalent in the drug delivery field, despite current research on natural polymers like dextran and chitosan.[63] The use of amphiphilic polymers, which include both hydrophilic and hydrophobic blocks, as dendrimers, micelles, and nanomicelles—polymeric carriers—in drug administration has been extensively studied. In water, amphiphiles have the most common and long-lasting shapes, such as micelles and vesicles made of polymers.[64] Hydrophilic medications are encased in the hydrophobic core of polymeric micelles, which are nanostructures with a hydrophilic exterior. In the meanwhile, hydrophilic medications may be contained within the aqueous interior of polymeric nanovesicles, which have bilayer structures with an aqueous core that separates the core from the external medium and integrates the hydrophobic molecules inside the membrane. Thus, hydrophilic and hydrophobic medications, including proteins, genetic material, and chemotherapeutic medicines, may be transported via polymeric vesicles.[65] physically entrap drug molecules in the hydrophobic core of polymeric micelles which are composed of a hydrophilic outer surface and a hydrophobic interior core encapsulation functional groups are not required. By chemically coupling the micelles with amphiphilic polymers, which prevents early drug release, loading may be improved. Transporting compounds with low or no water solubility via the hydrophobic core may increase the therapeutic window of lipophilic drugs. The formation of hydrophobic drug emboli following intravenous injection is further inhibited by this. Micelles are also known for their extended in vivo circulation and decreased chance of rapid drug clearance, both of which encourage drug accumulation at cancer cells. Polymeric micelles are an important new nanomedicine with innovative clinical diagnostic and therapeutic applications because of these characteristics.[66]

The Greek word "dendron," which signifies tree, meros, or branch, is the source of the term "dendrimer." In 1978, Buhleir and associates synthesized and reported the first compounds having molecular cavity topologies that were "cascade" and "nonskid chain-like." These molecules were eventually recognized by Buhleir and associates as the first forms of dendritic polymers.. Buhleir and colleagues later identified these molecules as the first

types of dendritic polymers. [67] Dendrimers are an additional kind of polymeric carrier used for medication targeting. These are well-articulated, structurally multibranched macromolecules with monodispersed globular components. Each of the three main parts of dendrimers the exterior surfaces with functional groups, internal branching units, and the focal point—has a distinct purpose. (their function is described in Table 2) Drugs that are polar or apolar are retained within dendrimers via hydrophobic fragmentation or electrostatic contact, respectively. Covalent coupling of drug molecules to exterior groups or noncovalent coupling to the interior cavity of dendrimers may occur via physical contact. Two examples of materials that may be connected by electrostatic contact are gene plasmids and nucleic acids. The covalent bond gives a more stable formulation for medication delivery. The nature of the relationship determines the medications' release.[27] The critical nanoscale design parameters—particle size, shape, surface, flexibility/rigidity, architecture, and elemental composition—must be carefully taken into account for a successful. [68]

Table. 2 Structural components of dendrimers.

Structural Components	Description/Function
Focal point (core)	The dendrimers core may consist of a polymeric substance, nanoparticle, or tiny molecule.
Free (void) spaces	These are empty spaces that might be used to carry or encapsulate medications between the core and internal branchings.
Interior branching	Dendrimer core and outer-surface groups are connected by Multibrnched globular units with covalently structured interior functional groups.
Exterior groups	These are the exterior hydrophilic or hydrophobic surface groups that make up the dendrimer-drug complex's cover.
Dendrimer–drug linkage	The drug's covalent or noncovalent connection with the dendrimer.

Monoclonal Antibodies and Fragments

Protein molecules called monoclonal antibodies are produced using recombinant DNA technology from hybridoma cells. A specific kind of monoclonal antibody is called a monoclonal antibody when used therapeutically. Monoclonal antibodies are defined as "monospecific antibodies that are produced by identical immune cells that are all clones of a unique parent cell." The use of monoclonal antibiotics as therapeutic agents to treat a range of chronic conditions, such as cancer and infectious diseases, is becoming more popular. They may be combined with radioisotopes, cytokines, bacterial toxins, chemotherapeutic medications, and enzymes that target tumors to increase their lethal effects.[69]

Current Developments, Obstacles, and Prospects

Monoclonal antibodies are defined as "monospecific antibodies that originate from similar immune cells that are all copies of a unique parent cell.". The use of monoclonal antibiotics as therapeutic agents to treat a range of chronic conditions, such as cancer and infectious diseases, is becoming more popular. They may provide regulated release and shield the drug from the outside environment. Nanotechnology has been used in a number of nanomedicine domains, including imaging, diagnostics, and drug/gene delivery. By covalently binding to a drug via a linker, antibody-drug conjugates, often referred to as immunoconjugates, are being studied as potential replacements for recombinant antibodies. prevents damage to nontargeted organs by enabling the specificity of monoclonal antibodies to target potent drugs to specified regions. Additional advancements include metal and magnetic nanoparticles, nanoemulsions, nanocapsules, smart capsules, cyclodextrins, microspheres, nanotubes, nanoshells, quantum dots, hydrogels, and natural and synthetic polymeric nanoparticles that are being studied for local and systemic targeting..[70]

Misconceptions

There are unsettling realities about targeted drug delivery that are misunderstood and ignored. The first is that targeting is merely a random distribution rather than being precise. Second, there is still some evidence linking targeted administration to the theory of receptor overexpression. Third, the Enhanced Permeability and Retention impact improves delivery; however, it is not as precise as targeted delivery. Fourth, getting to the tumor tissue does not always imply better delivery; there may be drug release before reaching the target region.[71]

Complex Manufacturing Processes

To create tailored medications, further steps in chemical synthesis and purification are needed. Among the associated challenges are longer deadlines, more costs, and additional quality control and regulatory processes. Nanocarrier design presents several related issues, including toxicity, biocompatibility, sensitivity, and scalability.[25,72]

Tumor Heterogeneity

The enormous variation both inside and across tumors adds to the difficulty. Additionally, there are stroma linked to the tumor and metastases, including fibroblasts and tumor-associated macrophages.[73]

Barely Predictable Practical Outcomes

The effectiveness of drug-targeting methods is still hotly contested in practice. The success of these

strategies is only anticipated due to the lack of clinically transferable models, highly specialized targets, and targets chosen with spatial and temporal expression that is in line with interventional needs.[74]

Barriers in Clinical Translation

The clinical translation of nanomedicines into human medicine faces significant challenges due to the unproven Enhanced Permeability and Retention effect in human oncology, the lower-than-anticipated accumulation of nanoparticles within tumors despite active targeting strategies, and the need to carefully consider, modify, and control various factors during the preparation and delivery of nanomedicines.[29] Targeting using nanoparticles is dependent on a number of physicochemical parameters, including hydrophobicity, surface modification, surface charge, and particle size. The toxicity of nanoparticles is currently poorly understood, and there are still several issues with targeted administration and selective binding that need to be resolved. Taking these issues into account today and with the development of nanoparticles in the future might result in a new, more successful paradigm for research and treatment.[75]

Advances in Clinical Extrapolation

The clinical expansion of targeted drug delivery systems has not yet been shown to be effective. This is only possible with sophisticated methods, repeatable carrier preparation techniques, and thorough and in-depth preclinical testing.[74]

Theranostic Approach

Nanomedicine's future is to combine targeted therapy and diagnostics into a single, centralized treatment system. This novel theranostic technique offers the potential for a highly selective, effective, and moderately sensitive treatment of cancer and other chronic diseases, which also results in more customized chemotherapy and improved patient outcomes.[17]

Cell-Specific Delivery

Receptor-targeted delivery holds great promise for the development of novel drug delivery methods for cell-specific distribution, improved biological products, and the identification of fresh therapeutic targets.[76]

Standardization, Good Laboratory Practice, and Advanced Models

The creation of targeted strategies needs to be continuously assessed in view of the growing knowledge of various post-administration activities. The rapid development of clinical translation will be accelerated by creating more accurate and predictive preclinical animal models, implementing standardized norms and excellent laboratory practices, improving our knowledge of carcinoma biology, and finding real biomarkers.[73]

Precision Medicine (Engineering Precision Nanoparticles)

The field of cancer chemotherapy has seen significant development because of precision medicine, which optimizes medication systems and designs for specific patients. Improving a drug's pharmacological and pharmacokinetic qualities without sacrificing its desired impact at the molecular targets is called accurate medicine. It is possible to precisely change a medication's absorption properties, how it acts in target and nontarget tissue, and how it is delivered in synergistic drug combinations.[75] The development and optimization of more focused lipid-based, polymeric, and inorganic nanoparticles may be able to overcome biological obstacles to efficient medication administration, which vary depending on the patient and the disease. By overcoming the many biological barriers present in various patient groups and illnesses, these created and optimized nanoparticles are ushering in the age of precision medicine.Among the prospective uses of nanoparticles in precision medicine are intracellular targeting, gene editing, and immunoactivation or suppression.[78]

From Nanoparticles to Nanorobots

Self-powered and computer-controlled, pharmacytes and nanorobotic drug delivery systems may distribute drugs to specific parts of the human body with digital precision, timing, and accuracy. It is not always necessary to endocytose; nanorobots might use transmembrane mechanical nanoinjectors to avoid penetrating a target cell. A potential development in the engineering area of medical nanorobotics will be the design, manufacturing, and therapeutic use of pharmacytes when nanomedicine is applied.[27]

Conclusion

In the medical sciences, targeted drug delivery is emerging as one of the most innovative techniques for disease detection and treatment. The more sophisticated form of Paul Ehrlich's "magic bullet" idea is nanomedicine. Targeted-delivery nanomedicines may be made from a wide range of nanoparticles. Among the most promising advances in medicine for the diagnosis and treatment of deadly diseases. Conjugated polymers, polymeric micelles, liposomes, dendrimers, and polymeric nanoparticles all have special structural properties that make it easier for medications to connect to them efficiently for targeted distribution. Many challenges related to drug-targeting strategies for clinical usage have been discovered, studied, and overcome, especially in the context of tumor treatment.. It may be possible to bring safer nanomedicine by combining multidisciplinary research, technical advancements, and experience.

References

1) Bae, Y. H., & Park, K. (2020). Advanced drug delivery 2020 and beyond: Perspectives

on the future. *Advanced Drug Delivery Reviews*, *158*, 4–16 https://doi.org/10.1016/j.addr.2020.06.018

2) Sun, Y., Chen, D., Pan, Y., Qu, W., Hao, H., Wang, X., Liu, Z., & Xie, S. (2019). Nanoparticles for antiparasitic drug delivery. Drug Delivery, 26(1), 1206–1221. https://doi.org/10.1080/10717544.2019.1692968

3) Tewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Abdela Siraj, E. (2021). Targeted Drug Delivery - From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. *Journal of multidisciplinary healthcare*, *14*, 1711–1724. https://doi.org/10.2147/JMDH.S313968

4) Bae, Y. H., & Park, K. (2011). Targeted drug delivery to tumors: myths, reality and possibility. Journal of controlled release : official journal of the Controlled Release Society, 153(3), 198–205. https://doi.org/10.1016/j.jconrel.2011.06.001

5) Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., Okoroafor, C. C., Eze, S. C., Kalu, O. L., Odoh, E. C., Nwadike, U. G., Ogbodo, J. O., Umeh, B. U., Ossai, E. C., & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. Heliyon, 9(6), e17488. https://doi.org/10.1016/j.heliyon 2023.e17488

6) Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., & Wang, J. (2022). Smart drug delivery systems for precise cancer therapy. Acta Pharmaceutica Sinica B, 12(11), 4098–4121. https://doi.org/10.1016/j.apsb.2022.08.013

7) Adepu, S., & Ramakrishna, S. (2021). Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules (Basel, Switzerland), 26(19), 5905. https://doi.org/10.3390/molecules26195905

8) Cheng, X., Xie, Q., & Sun, Y. (2023). Advances in nanomaterial-based targeted drug delivery systems. Frontiers in bioengineering and biotechnology, 11, 1177151. https://doi.org/10.3389/fbioe.2023.1177151

9) Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of controlled release : official journal of the Controlled Release Society, 342, 53–65. https://doi.org/10.1016/j.jconrel.2021.12.030

10) Ali, Y., Alqudah, A., Ahmad, S., Abd Hamid, S., & Farooq, U. (2019). Macromolecules as targeted drugs delivery vehicles: an overview. Designed Monomers and Polymers, 22(1), 91–97. https://doi.org/10.1080/15685551.2019.1591681

11) Akhtar, M., Jamshaid, M., Zaman, M., & Mirza, A. Z. (2020). Bilayer tablets: A developing novel drug delivery system. Journal of Drug Delivery Science and Technology, 60, 102079. https://doi.org/10.1016/j.jddst.2020.102079

12) Wittlin, S., & Mäser, P. (2021). From Magic Bullet to Magic Bomb: Reductive Bioactivation of Antiparasitic Agents. ACS Infectious Diseases, 7(10), 2777–2786. https://doi.org/10.1021/acsinfecdis.1c00118

13) Hasan, N., Imran, M., Jain, D., Jha, S. K., Nadaf, A., Chaudhary, A., Rafiya, K., Jha, L. A., Almalki, W. H., Mohammed, Y., Kesharwani, P., & Ahmad, F. J. (2023). Advanced targeted drug delivery by bioengineered white blood cell-membrane camouflaged nanoparticulate delivery nanostructures. Environmental Research, 238, 117007. https://doi.org/10.1016/j.envres.2023.117007

14) Bosch, F., & Rosich, L. (2008). The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology, 82(3), 171–179. https://doi.org/10.1159/000149583

15) Maxson, T., & Mitchell, D. A. (2016). Targeted Treatment for Bacterial Infections: Prospects for Pathogen-Specific Antibiotics Coupled with Rapid Diagnostics. Tetrahedron, 72(25), 3609–3624. https://doi.org/10.1016/j.tet.2015.09.069

16) Barz, M. (2015). Complexity and Simplification in the Development of Nanomedicines. Nanomedicine, 10(20), 3093–3097. https://doi.org/10.2217/nnm.15.146

17) Fahmy, T. M., Fong, P. M., Goyal, A., & Saltzman, W. M. (2005). Targeted for drug delivery. Materials Today, 8(8), 18–26. https://doi.org/10.1016/s1369-7021(05)71033-6

18) Dunuweera, S. P., Rajapakse, R. M. S. I., Rajapakshe, R. B. S. D., Wijekoon, S. H. D. P., Thilakarathna, M. G. G. S. N., & Rajapakse, R. M. G. (2018). Review on Targeted Drug Delivery Carriers Used in Nanobiomedical Applications. Current Nanoscience, 15(4), 382–397. https://doi.org/10.2174/1573413714666181106114247

19) Chowdhury, D. (2011). Carbon Nanotube for Drug Delivery and Controlled Release. In Elsevier eBooks (pp. 643–655). https://doi.org/10.1016/b978-0-08-088504-9.00518-3

20) Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., & Li, J. (2023). Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics, 15(9), 2233. https://doi.org/10.3390/pharmaceutics15092233

21) Yu, H., Yang, Z., Li, F., Xu, L., & Sun, Y. (2020). Cell-mediated targeting drugs delivery systems. Drug delivery, 27(1), 1425–1437. https://doi.org/10.1080/10717544.2020.1831103

22) Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018). Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduction and Targeted Therapy, 3(1). https://doi.org/10.1038/s41392-017-0004-3

23) Attri, K., Yadav, M., & Shrivastav, S. (2019). Nanoparticles: A Novel Approach for Targeted Delivery of Medicines. Journal of Drug Delivery and Therapeutics, 9(3), 734–739. https://doi.org/10.22270/jddt.v9i3.2721

24) Chen, S., Zhao, X., Chen, J., Chen, J., Kuznetsova, L., Wong, S. S., & Ojima, I. (2010). Mechanism-Based Tumor-Targeting Drug Delivery System. Validation of Efficient Vitamin Receptor-Mediated Endocytosis and Drug Release. Bioconjugate Chemistry, 21(5), 979–987. https://doi.org/10.1021/bc9005656

25) Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H. (2019). Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. Cancers, 11(5), 640. https://doi.org/10.3390/cancers11050640

26) Khanna, V. K. (2012). Targeted Delivery of Nanomedicines. ISRN Pharmacology, 2012, 1–9. https://doi.org/10.5402/2012/571394

27) Tewabe, A., Abate, A., Tamrie, M., Seyfu, A., & Abdela Siraj, E. (2021). Targeted Drug Delivery - From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. Journal of multidisciplinary healthcare, 14, 1711–1724. https://doi.org/10.2147/JMDH.S313968

28) Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021). Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. Journal of Personalized Medicine, 11(6), 571. https://doi.org/10.3390/jpm11060571

29) Sindhwani, S., Syed, A. M., Ngai, J., Kingston, B. R., Maiorino, L., Rothschild, J., MacMillan, P., Zhang, Y., Rajesh, N. U., Hoang, T., Wu, J. L. Y., Wilhelm, S., Zilman, A., Gadde, S., Sulaiman, A., Ouyang, B., Lin, Z., Wang, L., Egeblad, M., & Chan, W. C. W. (2020b). The entry of nanoparticles into solid tumours. *Nature Materials*, *19*(5), 566–575. https://doi.org/10.1038/s41563-019-0566-2

30) He, B., Sui, X., Yu, B., Wang, S., Shen, Y., & Cong, H. (2020b). Recent advances in drug delivery systems for enhancing drug penetration into tumors. *Drug Delivery*, *27*(1), 1474–1490. https://doi.org/10.1080/10717544.2020.1831106

31) Prabahar, K., Alanazi, Z., & Qushawy, M. (2021). Targeted Drug Delivery System: Advantages, Carriers and Strategies. Indian

Journal of Pharmaceutical Education and Research, 55(2), 346–353. https://doi.org/10.5530/ijper.55.2.72

32) Talegaonkar, S., & Vyas, S. P. (2005). Inverse targeting of diclofenac sodium to reticuloendothelial system-rich organs by sphere-in-oil-in-water (s/o/w) multiple emulsion containing poloxamer 403. Journal of drug targeting, 13(3), 173–178. https://doi.org/10.1080/10611860500065104

33) Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016). Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. Chemical Reviews, 116(9), 5338–5431. https://doi.org/10.1021/acs.chemrev.5b00589

34) Ahmad, W., Khan, T., Basit, I., & Imran, J. (2022). A Comprehensive Review on Targeted Drug Delivery System. Asian Journal of Pharmaceutical Research, 335–340. https://doi.org/10.52711/2231-5691.2022.00053Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D., & Kommineni, N. (2024). Receptor-Targeted Nanomedicine for Cancer Therapy. Receptors, 3(3), 323-361

35) Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D., & Kommineni, N. (2024). Receptor-Targeted Nanomedicine for Cancer Therapy. Receptors, 3(3), 323-361

36) Todaro, B., Ottalagana, E., Luin, S., & Santi, M. (2023). Targeting Peptides: The New Generation of Targeted Drug Delivery Systems. Pharmaceutics, 15(6), 1648. https://doi.org/10.3390/pharmaceutics15061648

37) Veselov, V. V., Nosyrev, A. E., Jicsinszky, L., Alyautdin, R. N., & Cravotto, G. (2022). Targeted Delivery Methods for Anticancer Drugs. Cancers, 14(3), 622. https://doi.org/10.3390/cancers14030622

38) Philip, A. K., & Philip, B. (2010). Colon targeted drug delivery systems: a review on primary and novel approaches. Oman medical journal, 25(2), 79–87. https://doi.org/10.5001/omj.2010.24

39) Bertrand, N., & Leroux, J. (2011). The journey of a drug-carrier in the body: An anatomo-physiological perspective. Journal of Controlled Release, 161(2), 152–163. https://doi.org/10.1016/j.jconrel.2011.09.098

40) Scott, R. C., Crabbe, D., Krynska, B., Ansari, R., & Kiani, M. F. (2008). Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opinion on Drug Delivery, 5(4), 459–470. https://doi.org/10.1517/17425247.5.4.459

41) Öztürk, K., Eroğlu, H., & Çalış, S. (2017). Novel advances in targeted drug delivery. Journal of Drug Targeting, 26(8), 633–642. https://doi.org/10.1080/1061186x.2017.1401076

42) Kudgus, R. A., Walden, C. A., McGovern, R. M., Reid, J. M., Robertson, J. D., & Mukherjee, P. (2014). Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component. Scientific reports, 4, 5669. https://doi.org/10.1038/srep05669

43) Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1–2), 1–20. https://doi.org/10.1016/s0168-3659(00)00339-4

44) Muzzalupo, R., & Tavano, L. (2015). Niosomal drug delivery for transdermal targeting: recent advances. Research and Reports in Transdermal Drug Delivery, 23. https://doi.org/10.2147/rrtd.s64773 Kamboj, S., Saini, V., Maggon, N., Bala, S., & Jhawat, V. (2013). VESICULAR DRUG DELIVERY SYSTEMS: A NOVEL APPROACH FOR DRUG TARGETING. International Journal of Drug Delivery, 5(2), 121–130. http://www.arjournals.org/index.php/ijdd/article/download/969/pdf

45) Arora, S., Lamba, H., & Tiwari, R. (2012). Dermal delivery of drugs using different

vesicular carriers: A comparative review. Asian Journal of Pharmaceutics, 6(4), 237. https://doi.org/10.4103/0973-8398.107558

46) Suttee, A., Mishra, V., Nayak, P., Singh, M., & Sriram, P. (2020). Niosomes: Potential Nanocarriers for Drug Delivery. International Journal of Pharmaceutical Quality Assurance, 11(03), 389–394. https://doi.org/10.25258/ijpqa.11.3.13

47) Kazi, K. M., Mandal, A. S., Biswas, N., Guha, A., Chatterjee, S., Behera, M., & Kuotsu, K. (2010). Niosome: A future of targeted drug delivery systems. Journal of advanced pharmaceutical technology & research, 1(4), 374–380. https://doi.org/10.4103/0110-5558.76435

48) Nsairat, H., Khater, D., Sayed, U., Odeh, F., Bawab, A. A., & Alshaer, W. (2022). Liposomes: structure, composition, types, and clinical applications. Heliyon, 8(5), e09394. https://doi.org/10.1016/j.heliyon.2022.e09394

49) Abu-Dahab, R., Schäfer, U. F., & Lehr, C. (2001). Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. European Journal of Pharmaceutical Sciences, 14(1), 37–46. https://doi.org/10.1016/s0928-0987(01)00147-6

50) Vemuri, S., & Rhodes, C. (1995). Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharmaceutica Acta Helvetiae, 70(2), 95–111. https://doi.org/10.1016/0031-6865(95)00010-7

51) Nakhaei, P., Margiana, R., Bokov, D. O., Abdelbasset, W. K., Jadidi Kouhbanani, M. A., Varma, R. S., Marofi, F., Jarahian, M., & Beheshtkhoo, N. (2021). Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol. Frontiers in bioengineering and biotechnology, 9, 705886. https://doi.org/10.3389/fbioe.2021.705886 (Retraction published Front Bioeng Biotechnol. 2023 Sep 04;11:1285118. doi: 10.3389/fbioe.2023.1285118)

52) Adepu, S., & Ramakrishna, S. (2021). Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules (Basel, Switzerland), 26(19), 5905. https://doi.org/10.3390/molecules26195905

53) Marianecci, C., Petralito, S., Rinaldi, F., Hanieh, P. N., & Carafa, M. (2015). Some recent advances on liposomal and niosomal vesicular carriers. Journal of Drug Delivery Science and Technology, 32, 256–269. https://doi.org/10.1016/j.jddst.2015.10.008

54) Kuotsu, K., Karim, K., Mandal, A., Biswas, N., Guha, A., Chatterjee, S., & Behera, M. (2010). Niosome: A future of targeted drug delivery systems. Journal of Advanced Pharmaceutical Technology Amp Research, 1(4), 374. https://doi.org/10.4103/0110-5558.76435

55) Rajan, R., Jose, S., Mukund, V. B., & Vasudevan, D. (2011). Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. Journal of Advanced Pharmaceutical Technology Amp Research, 2(3), 138. https://doi.org/10.4103/2231-4040.85524

56) Rao, B. N., Reddy, K. R., Mounika, B., Fathima, S. R., & Tejaswini, A. (2019). Vesicular Drug Delivery System: a review. International Journal of ChemTech Research, 12(05), 39–53. https://doi.org/10.20902/ijctr.2019.120505

57) Kumar, A. (2018). transferosome: a recent approach for transdermal drug delivery. Journal of Drug Delivery and Therapeutics, 8(5-s), 100–104. https://doi.org/10.22270/jddt.v8i5-s.1981

58) Pand Pandey, V., Golhani, D., & Shukla, R. (2014). Ethosomes: versatile vesicular carriers for efficient transdermal delivery of therapeutic agents. Drug Delivery, 22(8), 988–1002. https://doi.org/10.3109/10717544.2014.889777

59) Singh, M. N., Hemant, K. S. Y., Ram, M., & Shivakumar, H. G. (2010). Microencapsulation: A promising technique for controlled drug delivery. PubMed. https://pubmed.ncbi.nlm.nih.gov/21589795

60) Bale, S., Khurana, A., Reddy, A. S. S., Singh, M., & Godugu, C. (2016). Overview on Therapeutic applications of microparticulate drug delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems, 33(4), 309–361. https://doi.org/10.1615/critrevtherdrugcarriersyst.2016015798

61) Prasad, R. P. R., Pandey, R. P. R., Varma, A. V. A., & Barman, I. B. I. (2016). Polymer-based nanoparticles for drug delivery systems and cancer therapeutics. In CABI eBooks (pp. 53–70). https://doi.org/10.1079/9781780644479.0053

62) Uskokovic, D., & Stevanovic, M. (2009). Poly(lactide-co-glycolide)-based Micro and Nanoparticles for the Controlled Drug Delivery of Vitamins. Current Nanoscience, 5(1), 1–14. https://doi.org/10.2174/157341309787314566

63) Borandeh, S., Van Bochove, B., Teotia, A., & Seppälä, J. (2021). Polymeric drug delivery systems by additive manufacturing. Advanced Drug Delivery Reviews, 173, 349–373. https://doi.org/10.1016/j.addr.2021.03.022

64) Cardona, Y. V., Muñoz, L. G., Cardozo, D. G., & Chamorro, A. F. (2024b). Recent applications of amphiphilic copolymers in drug release systems for skin treatment. Pharmaceutics, 16(9), 1203. https://doi.org/10.3390/pharmaceutics16091203

65) Perumal, S., Atchudan, R., & Lee, W. (2022). A review of polymeric micelles and their applications. Polymers, 14(12), 2510. https://doi.org/10.3390/polym14122510

66) Ali, Y., Alqudah, A., Ahmad, S., Hamid, S. A., & Farooq, U. (2019). Macromolecules as targeted drugs delivery vehicles: an overview. Designed Monomers & Polymers, 22(1), 91–97. https://doi.org/10.1080/15685551.2019.1591681

67) Wang, J., Li, B., Qiu, L., Qiao, X., & Yang, H. (2022). Dendrimer-based drug delivery systems: history, challenges, and latest developments. Journal of Biological Engineering, 16(1). https://doi.org/10.1186/s13036-022-00298-5

68) Yang, H. (2015). Targeted nanosystems: Advances in targeted dendrimers for cancer therapy. Nanomedicine Nanotechnology Biology and Medicine, 12(2), 309–316. https://doi.org/10.1016/j.nano.2015.11.012

69) Quinteros, D. A., Bermúdez, J. M., Ravetti, S., Cid, A., Allemandi, D. A., & Palma, S. D. (2017). Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In Elsevier eBooks (pp. 807–833). https://doi.org/10.1016/b978-0-323-46143-6.00025-7

70) Martinho, N., Damgé, C., & Reis, C. P. (2011). Recent advances in drug delivery systems. Journal of Biomaterials and Nanobiotechnology, 02(05), 510–526. https://doi.org/10.4236/jbnb.2011.225062

71) Kwon, I. K., Lee, S. C., Han, B., & Park, K. (2012). Analysis on the current status of targeted drug delivery to tumors. Journal of Controlled Release, 164(2), 108–114. https://doi.org/10.1016/j.jconrel.2012.07.010

72) Freitas, R. A. (2006). Pharmacytes: an ideal vehicle for targeted drug delivery. Journal of Nanoscience and Nanotechnology, 6(9), 2769–2775. https://doi.org/10.1166/jnn.2006.413

73) Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-03705-y

74) Vhora, I., Patil, S., Bhatt, P., Gandhi, R., Baradia, D., & Misra, A. (2014). Receptor-targeted Drug delivery: Current Perspective and Challenges. Therapeutic Delivery, 5(9), 1007–1024. https://doi.org/10.4155/tde.14.63

75) Sultana, A., Zare, M., Thomas, V., Kumar, T. S., & Ramakrishna, S. (2022). Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and future prospects. Medicine in Drug Discovery, 15, 100134.

https://doi.org/10.1016/j.medidd.2022.100134

76) Oftedal, G. (2019). The role of "Missile" and "Targeting" metaphors in nanomedicine. Philosophia Scientae, 23–1, 39–55. https://doi.org/10.4000/philosophiascientiae.1742

77) Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021). Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 6(4), 351–370. https://doi.org/10.1038/s41578-020-00269-6

78) Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2020). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124. https://doi.org/10.1038/s41573-020-0090-8